Shares of Dyax Corp. (NASDAQ: DYAX), a biopharma company focused on developing treatments for rare blood disorders, fell more than 13% during September.
Given the share price weakness, is now a good time to considering making an investment in Dyax? See below for my take.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.
